Midazolam Accord (Midazolam)

Midazolam acts as a positive allosteric modulator at the benzodiazepine binding site of the GABA‑A receptor. By enhancing GABA‑mediated chloride influx, it hyperpolarizes neuronal membranes, leading to central nervous system depression that produces sedation, anxiolysis, amnesia, and anticonvulsant effects.

The dose of Midazolam Accord is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and intended use. Dosage regimens are individualized and should follow local guidelines and the prescriber’s judgment.

Safety data for midazolam in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made by the treating physician in consultation with the patient.

To request Midazolam Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Midazolam is a short‑acting benzodiazepine with rapid onset, making it useful for procedural sedation and induction of anesthesia. Compared with longer‑acting agents such as diazepam, midazolam provides quicker recovery times and more predictable pharmacokinetics, which can be advantageous in short procedures.

Midazolam Accord should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability and sterility.

Midazolam Accord is administered by a qualified healthcare professional via intramuscular or intravenous injection. The route, rate of administration, and monitoring depend on the clinical indication and patient condition, following institutional protocols.

The most serious risks include respiratory depression, severe hypotension, paradoxical reactions such as agitation, anaphylaxis, and cardiac arrhythmias. Continuous monitoring of respiratory and cardiovascular status is essential, especially when used with other depressant agents.

Midazolam should be avoided in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, or those taking contraindicated CNS depressants without appropriate monitoring. Individual assessment by a healthcare professional is required.